What is Bioequivalence?


Generics are not required to replicate the extensive clinical trials that have already been used in the development of the original, brand-name drug. These tests usually involve a few hundred to a few thousand patients. Since the safety and efficacy of the brand-name product has already been well established in clinical testing and frequently many years of patient use, it is scientifically unnecessary, and would be unethical, to require that such extensive testing be repeated in human subjects for each generic drug that a firm wishes to market. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent (i.e., per-forms in the same manner) to the pioneer drug. 

One way scientists demonstrate bioequivalence is to measure the time it takes the generic drug to reach the bloodstream and its concentration in the bloodstream in 24 to 36 healthy, normal volunteers, This gives them the rate and extent of absorption or bioavailability of the generic drug, which they then compare to that of the pioneer drug. The generic version must deliver the same amount of active ingredients into a patient's bloodstream in the same amount of time as the pioneer drug.

Using bioequivalence as the basis for approving generic copies of drug products was established by the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act. Brand-name drugs are subject to the same bio equivalency tests as generics when their manufacturers reformulate them.

Certified Hands-on Training on Clinical Trial Practices

Certified Hands-on HPLC Workshop

Upcoming Workshops

Like us on fb.com/PharmaProfessionalServices

Pharma Professional Services

Copyright Pharma Professional Services. All rights reserved.
No part of this site or the publications described herein may be reproduced without the permission of Pharma Professional Services. To obtain permission, please contact info@phaps.com

Threesome